December 05, 2023
1 min watch
Save
VIDEO: Trabectedin plus low-dose irinotecan promising in Ewing sarcoma
Sandra D’Angelo, MD, discussed a clinical trial on trabectedin in combination with low-dose irinotecan in Ewing sarcoma presented at the Connective Tissue Oncology Society Annual Meeting.
“The combination together was found to be quite efficacious,” D’Angelo, research director of the sarcoma medical oncology service at Memorial Sloan Kettering Cancer Center, said in the video interview.
Reference:
- Grohar PJ, et al. Paper 37. Presented at: Connective Tissue Oncology Society Annual Meeting; Nov. 1-4, 2023; Dublin.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interviews
Disclosures:
D’Angelo reports consulting/advising for Aadi Bioscience, Adaptimmune, Amgen, EMD Serono, GI Innovations, GSK, Immune Design, Immunocore, Incyte, Merck, Nektar, Pfizer, Rain Therapeutics and Servier; research funding from Amgen, Bristol Myers Squibb, Deciphera, EMD Serono, Incyte, Merck and Nektar; receiving travel/accommodations expenses from Adaptimmune, EMD Serono and Nektar; and being on a data safety monitoring board/advisory board for Adaptimmune, GSK, Merck and Nektar.
Read more about